Results 31 to 40 of about 10,075 (184)

Lung Transplant Recipients Immunogenicity after Heterologous ChAdOx1 nCoV-19—BNT162b2 mRNA Vaccination [PDF]

Viruses, 2022
(1) Background: High immunosuppressive regimen in lung transplant recipients (LTRs) hampers the immune response to vaccination. We prospectively investigated the immunogenicity of heterologous ChAdOx1 nCoV-19-BNT162b2 mRNA vaccination in an LTR cohort ...
Emilie Catry, Julien Favresse, Constant Gillot, Jean-Louis Bayart, Damien Frérotte, Michel Dumonceaux, Patrick Evrard, François Mullier, Jonathan Douxfils, François M. Carlier, Mélanie Closset   +10 more
doaj   +2 more sources

Myasthenia gravis with ocular symptoms following a ChAdOx1 nCoV-19 vaccination: A case report

American Journal of Ophthalmology Case Reports, 2022
Purpose: We report on the case of a 35-year-old man who developed myasthenia gravis with ocular symptoms following a ChAdOx1 nCoV-19 vaccine injection. Observations: A 35-year-old man complained of binocular diplopia one month following ChAdOx1 nCoV-19 ...
Min Chae Kang, Kyung-Ah Park, Ju-Hong Min, Sei Yeul Oh   +3 more
doaj   +3 more sources

Sinopharm’s BBIBP-CorV Vaccine and ChAdOx1 nCoV-19 Vaccine Are Associated with a Comparable Immune Response against SARS-CoV-2

Vaccines, 2022
Coronavirus disease 2019 (COVID-19) has affected millions of people worldwide. During the early stages of vaccination in Egypt, the ChAdOx1 nCoV-19 and BBIBP-CorV vaccines were the most distributed.
Ahmed Samir Abdelhafiz, Asmaa Ali, Mahmoud M. Kamel, Eman Hasan Ahmed, Douaa M. Sayed, Rania M. Bakry   +5 more
doaj   +2 more sources

Comparative effectiveness of BNT162b2 and ChAdOx1 nCoV-19 vaccines against COVID-19 [PDF]

BMC Medicine, 2023
Background Both BNT162b2 (Pfizer–BioNTech) and ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccines have shown high efficacy against COVID-19 in randomized controlled trials. However, their comparative effectiveness against COVID-19 is unclear in the real world.
Jie Wei, Weiya Zhang, Michael Doherty, Zachary S. Wallace, Jeffrey A. Sparks, Na Lu, Xiaoxiao Li, Chao Zeng, Guanghua Lei, Yuqing Zhang   +9 more
doaj   +2 more sources

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Lancet, The, 2021
Background A new variant of SARS-CoV-2, B.1.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020. We report a post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against this ...
Minassian, Angela M, Fuskova, Michelle, Green, Christopher A, Aley, Parvinder K, Bibi, Sagida, al., Et, Snape, Matthew, Angus, Brian, Plested, Emma, Kerridge, Simon, Hill, Adrian, Robinson, Hannah, Lambe, Teresa, Greenland, Melanie, Bonsall, David, Gilbert, Sarah, Ramasamy, Maheshi, Pollard, Andrew J, Dold, Christina, Voysey, Merryn, Green, Catherine M, Song, Rinn, Marchevsky, Natalie G, Golubchik, Tanya, Clutterbuck, Elizabeth A, Mujadidi, Yama F, Folegatti, Pedro M, Feng, Shuo, Emary, Katherine RW, Cicconi, Paola, Flaxman, Amy L, Douglas, Alexander D, Ewer, Katie J, Phillips, Daniel J, Jenkin, Daniel   +34 more
core   +3 more sources

Risk of Thrombosis Following the First Dose of ChAdOx1 nCoV-19 Vaccine in Patients Undergoing Maintenance Hemodialysis: A Self-Controlled Case Series Study

International Journal of General Medicine, 2023
Shih-Chieh Shao,1,2 Tzu-Chi Liao,1 Kai-Cheng Chang,1,3 Hui-Yu Chen,3 Swu-Jane Lin,4 Cheng-Yang Hsieh,1,5 Edward Chia-Cheng Lai1 1School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung ...
Shao SC, Liao TC, Chang KC, Chen HY, Lin SJ, Hsieh CY, Lai ECC   +6 more
doaj   +1 more source

ChAdOx1 nCoV-19 vaccine for SARS-CoV-2 [PDF]

The Lancet, 2020
Chauhan, Anil, Agarwal, Amit, Jaiswal, Nishant, Singh, Meenu   +3 more
exaly   +7 more sources

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination [PDF]

Neurological Research and Practice, 2022
AbstractA 71-year-old male patient was diagnosed with LGI1 encephalopathy 4 weeks following a first ChAdOx1 nCov-19 vaccination. Extensive work-up including analysis of CSF and PET examination did not reveal a tangible cause so that a vaccine-associated encephalopathy was considered as differential diagnosis.
Tamara Garibashvili, Josef Georg Heckmann   +1 more
openaire   +4 more sources

Incidence of anti-platelet factor4/polyanionic antibodies, thrombocytopenia, and thrombosis after COVID-19 vaccination with ChAdOx1 nCoV-19 in Thais [PDF]

Thrombosis Journal, 2023
Background The prevalence of anti-platelet factor 4 (PF4)/polyanionic antibodies occurring after vaccination with ChAdOx1 nCoV-19 is low. Most of these antibodies are not associated with vaccine-induced thrombotic thrombocytopenia.
Kochawan Boonyawat, Tichayapa Phojanasenee, Phichchapha Noikongdee, Pornnapa Police, Pichika Chantrathammachart, Pimjai Niparuck, Teeraya Puavilai, Angsana Phuphuakrat, Pantep Angchaisuksiri   +8 more
doaj   +2 more sources

Venous sinus thrombosis following vaccination with ChAdOx1 nCov-19 [PDF]

Medicina Intensiva (English Edition), 2022
Morales Varas, G., Calle Flores, A., Sánchez Casado, M.   +2 more
openaire   +4 more sources